Press Releases
Looking for more press releases? Explore our full press release archive by date to access past announcements, news updates, and media releases published on Reunion Technology Digest.
Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S.
GlobeNewswire, Inc.
·
August 25, 2025
Saint Herblain (France), August 25, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four...
Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities
GlobeNewswire, Inc.
·
April 26, 2025
Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France’s national public health agency, the Haute Autorité de Santé (HAS), has updated its recommendation...
Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion
GlobeNewswire, Inc.
·
March 24, 2025
Saint Herblain (France), March 24, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it is responding to the chikungunya outbreak that is rapidly intensifying in France’s Island of La Réunion...
Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates
GlobeNewswire, Inc.
·
August 12, 2025
Total revenues of €97.6 million compared to €70.8 million in the first half of 2024 Cash and cash equivalents of €161.3 million at end of June 2025 Further clinical and regulatory progress 2025 financial outlook confirmed Saint-Herblain (France),...
WHO Cautions Chikungunya Spread Threatens Billions
MENAFN
·
July 22, 2025
(MENAFN) The World Health Organization (WHO) issued a stark warning Tuesday, cautioning that the world may be on the brink of reliving the devastating 2005 chikungunya epidemic unless swift containment measures are taken. "Chikungunya is not a...
EU Balance of Payments and International Investment Position statistical sources and methods - B.o.p. and i.i.p. e-book
ECB - European Central Bank
·
July 22, 2025
Introduction The European Central Bank (ECB), with the support of the European System of Central Bank’s (ESCB’s) Statistics Committee, compiles and publishes the balance of payments (b.o.p.) and the international investment position (i.i.p.) of...
Combined General Meeting of June 11, 2025
GlobeNewswire, Inc.
·
May 15, 2025
Châtillon, France, May 15, 2025 Combined General Meeting of June 11, 2025 Procedures for Obtaining Information and Preparatory Documents for the Combined General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®
GlobeNewswire, Inc.
·
June 5, 2025
IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after six months in both dose groups, although more robust with the full dose Six-month...
Combined General Meeting of June 13, 2025
GlobeNewswire, Inc.
·
May 23, 2025
Combined General Meeting of June 13, 2025 Access to information Paris, France – May 23, 2025 – Atos SE shareholders are invited to attend the Combined General Meeting of the Company to be held on Friday, June 13, 2025 at 10 a.m. (Paris time) at...
Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States
GlobeNewswire, Inc.
·
May 12, 2025
Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC), in a...
Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly
GlobeNewswire, Inc.
·
May 7, 2025
Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Valneva’s single-dose live attenuated chikungunya...
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers
GlobeNewswire, Inc.
·
April 18, 2025
Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for Disease Control and Prevention’s (CDC)...
National Personal Chef Day Spotlights a $16.88B Industry Transforming Luxury Dining at Home
EIN Presswire
·
July 16, 2025
On National Personal Chef Day, a $16.88B industry redefines luxury platforms like Chef2Nite turn home dining into bespoke, unforgettable experiences. MIAMI , FL, UNITED STATES, July 16, 2025 /EINPresswire.com/ -- As Americans increasingly seek...
Native American Photography Book 'Dancing for Our Tribe' by Sharon Hoogstraten
EIN Presswire
·
July 14, 2025
Dancing for Our Tribe is a visual feast of more than 150 full-color portraits of tribal members in traditional regalia, showing readers, “We are still here.” CHICAGO, IL, UNITED STATES, July 14, 2025 /EINPresswire.com/ -- “We Are Still Here”...
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above
GlobeNewswire, Inc.
·
April 1, 2025
With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint Herblain (France), April 1, 2025 – Valneva SE...
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA
GlobeNewswire, Inc.
·
March 31, 2025
Saint Herblain (France), March 31, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency...
EDITORIAL: “But who will pick our olives?” – Demographic decline and refugee inclusion
European Council on Refugees and Exiles (ECRE)
·
May 8, 2025
By Catherine Woollard Week after week, newspaper articles and research publications sound the alarm on the impact of Europe’s demographic crisis. Last week, a piece put the spotlight on Poland, arguing that this is not just an economic question...
Convening of the Annual General Meeting to approve the 2023 financial statements to be held on January 31, 2025 and evolution of the Atos Board of Directors
GlobeNewswire, Inc.
·
December 19, 2024
Communiqué de presse Convening of the Annual General Meeting to approve the 2023 financial statements to be held on January 31, 2025 and evolution of the Atos Board of Directors Paris, France, December 19, 2024 Convening of Annual General Meeting...
Combined General Meeting of January 31, 2025 - Access to information
GlobeNewswire, Inc.
·
January 10, 2025
Combined General Meeting of January 31, 2025 Access to information Paris, France, January 10, 2025. Atos SE shareholders are invited to attend the Combined General Meeting of the Company to be held on Friday, January 31, 2025 at 10 a.m. (Paris...
TRiCares presents promising First-In-Human Topaz data at EuroPCR 2025
GlobeNewswire, Inc.
·
May 22, 2025
Early results demonstrate near-complete elimination of tricuspid regurgitation in implanted patients with favorable safety profile and no permanent pacemaker implantations Paris, France and Munich, Germany, 22 May, 2025 – TRiCares SAS...